🇺🇸 FDA
Pipeline program

SPN-812

812P413

Approved small_molecule active

Quick answer

SPN-812 for Attention-Deficit/Hyperactivity Disorder is a Approved program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 3 ClinicalTrials.gov record(s).

Program details

Company
SUPERNUS PHARMACEUTICALS, INC.
Indication
Attention-Deficit/Hyperactivity Disorder
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials